SCHEMBL890802

SCHEMBL890802

CC(c1c(-c2cc(F)cc(F)c2)c(=O)c2cc(F)ccc2n1C)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.48
ATM Q13315 1/20 0.40
ALDH1A1 P00352 1/20 0.38
ALOX15 P16050 1/20 0.38
NTRK1 P04629 2/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
HCRTR1 O43613 1/20 0.36
MAPK14 Q16539 1/20 0.35
MET P08581 3/20 0.34
BRD4 O60885 1/20 0.34
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HTR1A P08908 1/20 0.33
PER2 O15055 1/20 0.33
CRY2 Q49AN0 1/20 0.33
CYP2C9 P11712 1/20 0.33
PTGDR Q13258 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10107682 0.81 PIK3CD (0.56) PIK3CDATMALDH1A1KMT2AMEN1
SCHEMBL890583 0.81 PIK3CD (0.53) PIK3CDATMALDH1A1KMT2AMEN1
SCHEMBL890541 0.75 PIK3CD (0.47) PIK3CDALDH1A1METLMNA
SCHEMBL890540 0.75 PIK3CD (0.47) PIK3CDALDH1A1METLMNA
SCHEMBL13062911 0.70 CTDSP1 (0.40) PIK3CDMETLMNA
SCHEMBL890554 0.70 PIK3CD (0.43) PIK3CDATMALDH1A1KMT2AMEN1
SCHEMBL2729228 0.69 PIK3CD (0.45) PIK3CDKMT2AMEN1HSD17B10
SCHEMBL2721074 0.69 PIK3CD (0.45) PIK3CDKMT2AMEN1HSD17B10
SCHEMBL2720585 0.69 DHODH (0.41) PIK3CDKMT2AMEN1METLMNA
SCHEMBL2731485 0.68 PIK3CD (0.47) PIK3CDMETBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
US-8754089-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-17 US disclosed
EP-2445898-A2 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES AS PI3K INHIBITORS Amgen, Inc (US) 2012-05-02 EP disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-05 US disclosed
WO-2010151735-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083502-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CD 24/4885ATM 639/4885ALDH1A1 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.